Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | CTSS | P25774 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22799711 | 0.98 | CAPN1 (0.47) | CAPN1KDM4ECTSSMEN1KMT2A | |
| SCHEMBL22800135 | 0.89 | CAPN1 (0.49) | CAPN1CTSSCTSKCTSB | |
| SCHEMBL22800194 | 0.88 | CAPN1 (0.47) | CAPN1KDM4ECTSSMEN1KMT2A | |
| SCHEMBL22800133 | 0.77 | LIG1 (0.46) | CAPN1KDM4ECTSSMEN1KMT2A | |
| SCHEMBL22800999 | 0.77 | CAPN1 (0.47) | CAPN1CTSSHTTCTSK | |
| SCHEMBL22800166 | 0.76 | L3MBTL1 (0.36) | CAPN1KDM4EMEN1KMT2AHTT | |
| SCHEMBL22800186 | 0.75 | ICMT (0.37) | CAPN1KDM4EMEN1KMT2AHDAC3 | |
| SCHEMBL22799838 | 0.74 | ALDH1A1 (0.51) | CAPN1KDM4EMEN1KMT2A | |
| SCHEMBL22800173 | 0.72 | ALDH1A1 (0.46) | KDM4EMEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL22800187 | 0.70 | ALDH1A1 (0.47) | KDM4EKMT2AHTTSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN2, CAPN1 | CAPN1 3/4885KDM4E 1957/4885CTSS 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.